A non‐competitive inhibitor of PHGDH, CBR‐5884, has been identified to block the de novo synthesis of serine in melanoma and breast cancer cells, being selectively toxic for cancer cells lines with high serine biosynthesis [97]. The gene discussed is PHGDH; the disease is cancer.